Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials
Article In Press
Robin M. Pokrzywinski, Ph.D., Ahmed M. Soliman, Ph.D., Jun Chen, M.S., Michael Snabes, Ph.D., Michael P. Diamond, M.D., Eric Surrey, M.D., Karin S. Coyne, Ph.D.
To estimate the impact of elagolix on work loss due to endometriosis-associated pain.
Post hoc analysis of data from the Elaris I and II clinical trials.
Employed women ages 18–49 years with moderate-to-severe endometriosis-associated pain.
In the two trials, participants were randomized to 6 months of treatment with placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day.
Main Outcome Measure(s)
Data on planned work hours, presenteeism, absenteeism, and total work loss (absenteeism + presenteeism) at baseline and month 3 were collected using the Health-Related Productivity Questionnaire.
This analysis included employed participants from EM-I (n = 672) and EM-II (n = 626). Between baseline and month 3, compared with participants treated with placebo, participants treated with elagolix 150 mg once a day gained > 2 hours total work/week (EM-I, 2.20 ± 1.03; EM-II, 2.65 ± 1.14). Participants treated with 200 mg twice a day gained > 4 hours total work/week (EM-I, 4.91 ± 1.04; EM-II, 4.64 ± 1.14). Both absenteeism and presenteeism were reduced, although most of the gain was due to reduced presenteeism. Estimated cost savings after 6 months of treatment with elagolix were > $1,500 U.S. at 150 mg once a day and > $3,300 U.S. at 200 mg twice a day.
Compared with placebo, treating moderate-to-severe endometriosis-associated pain with elagolix reduced absenteeism and improved productivity in employed women, which should result in cost savings.